RSV Vaccine for Infants: Fall Availability Announced

GGD Hollands Noorden to Host Informative Webinar on New RS Virus Protection for Infants

Effective Autumn 2025, infants born on or after April 1, 2025, will be eligible for a new preventative shot against the Respiratory Syncytial (RS) virus. To ensure expectant and new parents are well-informed about this significant public health growth, GGD Hollands Noorden is organizing a complimentary online webinar on Monday, September 23rd.

The RS virus is a prevalent cold virus among young children, especially during the autumn and winter months. While most children experience mild symptoms, infants are at a higher risk of developing severe complications such as bronchiolitis or pneumonia. Annually, an estimated 1 to 2 percent of infants are hospitalized due to RS virus infections.

The new preventative measure involves an injection of Nirsemimab, a substance containing antibodies that directly target the virus. Unlike vaccinations where the body produces its own antibodies, this method, known as immunization, provides immediate protection. A single dose offers approximately five to six months of protection against severe RS virus infections. Starting in 2025, this injection will be integrated into the National Vaccination Program and will be administered free of charge through the GGD.

Babies born between April and September 2025 will receive the shot at their scheduled consultation office appointments in September or October. for infants born from October 2025 through March 2026,the injection will be administered at home within two weeks of birth.

Side effects from the RS virus shot are generally minimal, potentially including temporary redness or tenderness at the injection site, a skin rash, or a mild fever. While fever is rare, parents are advised to contact their doctor if their child develops a fever.It is crucial to note that this protection is exclusively for infants born on or after April 1,2025,and is not available for babies born prior to this date through either consultation offices or general practitioners.

The GGD Hollands Noorden’s webinar on September 23rd aims to provide parents with comprehensive information and an opportunity to have their questions answered. Further details and registration information can be found on the GGD Hollands Noorden website. Parents can also access extensive information on the RIVM (National Institute for Public Health and the Habitat) websites and through materials related to the National Vaccination Program.

What age range of infants is Beyfortus recommended for during their first RSV season?

Understanding Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. However,for infants adn young children,RSV can lead to serious illness,including bronchiolitis and pneumonia. It’s a leading cause of hospitalization in infants, accounting for approximately 60% of infant hospitalizations due to lower respiratory tract infections. Protecting your little one from RSV is now more achievable than ever with newly available vaccines. This article will cover everything you need to know about the RSV vaccine for infants, including availability, who should get it, and what to expect.

The New RSV Vaccines: A breakthrough in Infant Health

For decades, scientists have been working to develop an effective RSV vaccine. in 2023 and continuing into 2024, several promising vaccines received FDA approval. These vaccines represent a significant breakthrough in protecting infants from the severe complications of RSV.

Here’s a breakdown of the currently approved options:

Arexvy (GSK): Approved for adults 60 years and older. While not directly for infants, protecting caregivers can indirectly protect babies.

Abrysvo (Pfizer): Approved for both older adults and for maternal vaccination during pregnancy (32-36 weeks gestation) to protect their babies.

Beyfortus (nirsevimab – Sanofi and AstraZeneca): A long-acting monoclonal antibody administered as a single dose to infants directly, providing protection for the entire RSV season. This is not a conventional vaccine, but offers passive immunity. Recent research highlights broad neutralization capabilities,like the RSV-199 antibody,capable of combating both RSV and hMPV [1].

Who Should Receive the RSV Vaccine or Immunization?

The recommendations for RSV protection vary depending on the method:

Maternal Vaccination (Abrysvo): Recommended for pregnant individuals between 32 and 36 weeks of gestation during RSV season (typically fall and winter).This provides antibodies to the baby in utero.

Infant Immunization (Beyfortus): Recommended for all infants younger than 8 months born during or entering their first RSV season. It’s also recommended for some older infants (8-19 months) who are at increased risk for severe RSV disease, such as those with chronic lung disease or congenital heart disease.

Caregiver Vaccination (Arexvy): While not a direct infant protection method, vaccinating parents, grandparents, and other caregivers can reduce the risk of them transmitting RSV to the baby.

Timing and Availability: Fall 2025 Outlook

The CDC and medical professionals recommend timing the governance of these protections to coincide with the RSV season,which typically begins in the fall and peaks during the winter months.

Fall 2025 Availability: Expect widespread availability of Beyfortus and continued access to Abrysvo for maternal vaccination starting in August/September 2025. healthcare providers are preparing for increased demand and are encouraging parents to schedule appointments early.

Insurance coverage: Most insurance plans now cover the RSV vaccine and beyfortus. Check with your insurance provider for specific coverage details and potential out-of-pocket costs. The vaccines for Children (VFC) program may also provide free or low-cost vaccines to eligible children.

What to Expect: Side Effects and Effectiveness

Like all vaccines and immunizations, the RSV vaccine and Beyfortus may cause mild side effects.

Maternal Vaccine (Abrysvo) Side Effects: Common side effects in pregnant individuals include pain at the injection site, fatigue, headache, and muscle aches.

Infant Immunization (Beyfortus) Side Effects: Beyfortus generally has a very good safety profile. The most common side effect is redness or swelling at the injection site.

* Effectiveness: Clinical trials have shown that both maternal vaccination and infant immunization are highly effective in preventing severe RSV disease. Studies demonstrate a significant reduction in